AMAG AMAG Pharmaceuticals Inc.

16.8
-0.19  -1%
Previous Close 16.99
Open 16.81
Price To Book 0.76
Market Cap 580199071
Shares 34,535,659
Volume 587,717
Short Ratio
Av. Daily Volume 783,728

SEC filingsSee all SEC filings

  1. 8-K - Current report 181232137
  2. 8-K - Current report 181174999
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181155568
  4. 8-K - Current report 181155537
  5. 8-K - Current report 181151968

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2/3 top-line data due 1H 2020.
Digoxin immune fab (DIF)
Severe preeclampsia in pregnant women
Phase 3 data due 1H 2019.
Intrarosa
Hypoactive sexual desire disorder (HSDD)
PDUFA date March 23, 2019 but noted November 13, 2018 that a 3-6 month delay is likely due to FDA request for further data.
Vyleesi (Bremelanotide)
Female sexual dysfunction (FSD)
Approval for sNDA filing announced February 5, 2018.
Feraheme
Adults with iron deficiency anemia (IDA)
Approval announced February 14, 2018.
Makena - auto injector
Reduce the risk of preterm birth in women with a singleton pregnancy

Latest News

  1. AMAG to Acquire Ciraparantag Maker Perosphere Pharmaceuticals
  2. AMAG Pharmaceuticals Enters Into Definitive Merger Agreement to Acquire Perosphere Pharmaceuticals
  3. Estimating The Fair Value Of AMAG Pharmaceuticals Inc (NASDAQ:AMAG)
  4. Study of Feraheme demonstrates Improvements in Fatigue and Quality Of Life in Iron Deficiency Anemia Patients
  5. Paul Tudor Jones Continues to Buy Apple, Alibaba
  6. AMAG Pharmaceuticals Awards Four Grants to Further Research in Preterm Birth and Preeclampsia
  7. AMAG's Label Expansion of Lead Products Raises Share Price
  8. Detailed Research: Economic Perspectives on KB Home, Lennox International, CorVel, Acorda Therapeutics, PROS, and AMAG Pharmaceuticals — What Drives Growth in Today's Competitive Landscape
  9. Edited Transcript of AMAG earnings conference call or presentation 1-Nov-18 12:00pm GMT
  10. AMAG Pharmaceuticals to Present at Upcoming Investor Conferences
  11. AMAG Posts Wider-Than-Expected Q3 Loss, Beats on Revenues
  12. Here's Why AMAG Pharmaceuticals Tumbled 12.7% Today
  13. AMAG Pharmaceuticals Inc (AMAG) Q3 2018 Earnings Conference Call Transcript
  14. AMAG Pharmaceuticals (AMAG) Reports Q3 Loss, Tops Revenue Estimates
  15. AMAG Pharmaceuticals: 3Q Earnings Snapshot
  16. AMAG Pharmaceuticals Announces Third Quarter 2018 Financial Results and Provides Corporate Update
  17. The Zacks Analyst Blog Highlights: Allergan, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and AMAG Pharmaceuticals
  18. 5 Drug/Biotech Stocks Likely to Beat Estimates in Q3 Earnings
  19. AMAG Pharmaceuticals (AMAG) Q3 Earnings Preview: What to Watch Ahead of the Release
  20. AMAG Pharmaceuticals to Host Third Quarter 2018 Financial Results Conference Call and Webcast on Thursday, November 1, 2018 at 8:00 a.m. ET

SEC Filings

  1. 8-K - Current report 181232137
  2. 8-K - Current report 181174999
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181155568
  4. 8-K - Current report 181155537
  5. 8-K - Current report 181151968
  6. 8-K - Current report 181086845
  7. CT ORDER - Confidential treatment order 181064761
  8. 8-K - Current report 181006211
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 18990499
  10. S-8 - Securities to be offered to employees in employee benefit plans 18990395